Related Experiment Video

Updated: Jul 27, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K

Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer

Shenduo Li1, Guilherme Sacchi de Camargo Correia1, Jing Wang2

  • 1Division of Hematology and Medical Oncology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA.

Cancers
|June 10, 2023
PubMed

Insights

This review covers new targeted therapies for advanced non-small-cell lung cancer (NSCLC) and discusses overcoming treatment resistance. It highlights emerging drugs in early-stage clinical trials for NSCLC patients.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Lung cancer is a leading global cause of cancer mortality.
  • Non-small-cell lung cancer (NSCLC) presents a significant challenge, particularly in advanced stages.
  • Targeted therapy has improved outcomes for NSCLC patients with specific mutations, but resistance remains a major hurdle.

Purpose of the Study:

  • To review emerging targeted therapies for NSCLC.
  • To focus on treatments investigated in first-in-human clinical trials within the last year.
  • To address the unmet need for drugs targeting previously untreatable mutations and overcoming therapy resistance.

Main Methods:

  • Literature review of recent clinical trials.
  • Focus on first-in-human studies.
  • Analysis of emerging targeted agents for NSCLC.

Main Results:

  • Identification of novel targeted therapies in early development.
  • Summary of ongoing clinical investigations for NSCLC.
  • Insights into strategies for overcoming treatment resistance in NSCLC.

Conclusions:

  • Emerging targeted therapies show promise for NSCLC treatment.
  • Continued research and clinical trials are crucial for advancing NSCLC care.
  • Addressing therapy resistance and targeting new mutations are key priorities.
Keywords:
EGFRNSCLCclinical trialfirst-in-humanphase I/IItargeted therapy

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
575
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K